PMV Pharmaceuticals, Inc.PMVPNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | -191.89% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | -191.89% |
| Weighted Average Shares Growth | +0.25% | +0.98% | +1.03% | +2.75% | +3.31% |
| Weighted Average Shares Diluted Growth | +0.25% | +0.98% | +1.03% | +2.75% | +3.31% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | -24.14% | -27.98% | -35.65% | -40.11% | -39.06% |
| Book Value per Share Growth | -22.18% | -25.45% | -35.06% | -40.50% | -42.44% |
| Debt Growth | -91.04% | -91.51% | -92.15% | -92.98% | -29.58% |
| R&D Expense Growth | +5.71% | +36.00% | +28.84% | +7.26% | +14.72% |
| SG&A Expenses Growth | +106.54% | -18.11% | -19.18% | -12.73% | -70.05% |